Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-based Compensation (Tables)

Stock-based Compensation (Tables)

6 Months Ended

Jun. 30, 2017

Schedule of stock-based compensation expense related to all of the entity's share-based awards

Total stock-based compensation expense related to all of our share-based payments that we recognized for the three and six months ended June 30, 2017 and 2016 were as follows (in thousands):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2016		2017		2016
General and administrative	$	764	$	604	$	1,359	$	1,349
Research and development		336		1,410		696		2,103
Total stock-based compensation expense	$	1,100	$	2,014	$	2,055	$	3,452

Summary of weighted-average assumptions relating to options granted pursuant to equity incentive plans


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2016		2017		2016
Risk-free interest rate	2.1	%	1.5	%	2.2	%	1.7	%
Expected term (in years)	6.6		7.0		6.8		6.4
Dividend yield	0.0	%	0.0	%	0.0	%	0.0	%
Expected volatility	63.7	%	76.9	%	63.0	%	63.3	%

Summary of weighted-average assumptions used to calculate fair value of purchase rights granted under Employee Stock Purchase Plan


	Six Months Ended
	June 30,
	2017		2016
Risk-free interest rate	0.5	%	0.7	%
Expected term (in years)	1.5		1.8
Dividend yield	0.0	%	0.0	%
Expected volatility	63.1	%	61.5	%